Brief: XBiotech To Launch Novel Candidate Therapy For Stroke
28/10/2021 16:59
Oct 28 (Reuters) - XBiotech Inc XBIT.O :
* XBIOTECH TO LAUNCH NOVEL CANDIDATE THERAPY FOR STROKE
* XBIOTECH INC - COMMENCING PHASE I/II STUDY TO TEST SAFETY
AND
EFFICACY OF ITS NEW DRUG CANDIDATE TO REDUCE BRAIN INJURY AFTER
STROKE
Source text for Eikon: ID:nGNE1nbF2Y
Further company coverage: XBIT.O
((Reuters.briefs@thomsonreuters.com;))
Recent news on XBiotech
See all newsBrief: XBiotech Announces Positive Final Efficacy Results From Phase II Taskin Trial
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: XBiotech Inc - John Simard To Retire As CEO Of XBiotech - SEC Filing
Brief: Xbiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke